![conference banner](/images/conference-banner.jpeg)
Abstract
Over the last decade several pharmacological approaches for acute heart failure have been introduced, however, no drastic change in the medical management apart from device-dependent therapy was observed. Essentially vasodilators and diuretics as primary therapy in acute heart failure was discussed and encouraged in the guidelines but no breakthrough in the treatment of acute heart failure was achieved. More recently, clinical trials of relaxin and its recombinant form, i.e., serelaxin in patients with acute heart failure demonstrated a significant clinical improvement with favorable safety and tolerability profile in symptomatic heart failure patients. This report reviews the potential beneficial effects and role of serelaxin in the setting of acute heart failure.
Keywords: Acute heart failure, cardiac failure, cardiovascular diseases, cognitive impairment, dyspnea, hospitalized patients, ischemic cardiomyopathy, non-ischemic cardiomyopathy, relaxin, serelaxin, vasodilator.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Serelaxin: New Investigational Treatment in Acute Heart Failure
Volume: 11 Issue: 3
Author(s): Sarmad Said and Debabrata Mukherjee
Affiliation:
Keywords: Acute heart failure, cardiac failure, cardiovascular diseases, cognitive impairment, dyspnea, hospitalized patients, ischemic cardiomyopathy, non-ischemic cardiomyopathy, relaxin, serelaxin, vasodilator.
Abstract: Over the last decade several pharmacological approaches for acute heart failure have been introduced, however, no drastic change in the medical management apart from device-dependent therapy was observed. Essentially vasodilators and diuretics as primary therapy in acute heart failure was discussed and encouraged in the guidelines but no breakthrough in the treatment of acute heart failure was achieved. More recently, clinical trials of relaxin and its recombinant form, i.e., serelaxin in patients with acute heart failure demonstrated a significant clinical improvement with favorable safety and tolerability profile in symptomatic heart failure patients. This report reviews the potential beneficial effects and role of serelaxin in the setting of acute heart failure.
Export Options
About this article
Cite this article as:
Said Sarmad and Mukherjee Debabrata, Serelaxin: New Investigational Treatment in Acute Heart Failure, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/1871525711666131128144132
DOI https://dx.doi.org/10.2174/1871525711666131128144132 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atherosclerotic Renal Artery Stenosis: An Update on Diagnosis and Management
Current Vascular Pharmacology Uteroplacental Circulation and Fetal Vascular Function and Development
Current Vascular Pharmacology Novel Vitreous Modulators for Pharmacologic Vitreolysis in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Dual Inhibitors of β-Amyloid Aggregation and Acetylcholinesterase as Multi-Target Anti-Alzheimer Drug Candidates
Current Topics in Medicinal Chemistry Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Hesperidin: A Potential Therapeutic Agent against COVID-19
Current Drug Discovery Technologies The In Silico Prediction of Human-Specific Metabolites from Hepatotoxic Drugs
Current Drug Discovery Technologies Opioids, Sleep, and Sleep-Disordered Breathing
Current Pharmaceutical Design Cyclosporine A: Chemistry and Toxicity – A Review
Current Medicinal Chemistry The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design New Therapies to Modulate Post-Infarction Inflammatory Alterations in the Myocardium: State of the Art and Forthcoming Applications
Current Radiopharmaceuticals Progress of Antiplatelet Pharmacogenomics
Current Drug Targets Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Modelling Anxiety in Humans for Drug Development
Current Neuropharmacology Adjunctive Strategies in the Management of Resistant, ‘Undilatable’ Coronary Lesions After Successfully Crossing a CTO with a Guidewire
Current Cardiology Reviews The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Inappropriate Use of Proton Pump Inhibitor Among Elderly Patients in British Columbia: What are the Long-term Adverse Events?
Current Drug Safety Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry